Akanda Corp. (AKAN) Stock Analysis

Company Overview

Akanda Corp. (AKAN) is capitalised at $1.81M on the latest close. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry.

The 52-week range on file runs from $2.30 to $209.23. AKAN last closed at $3.35 on September 4, 2026. That is −$0.32 (−8.72%) against the previous close. The latest close sits 45.82% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $258.08K. The same year closed with a net loss of $45.65M. The reported profit margin is 0%. That is 3.1 percentage points above the Drug Manufacturers - Specialty & Generic median of −3.14%.

Across the 4 fiscal years on file, revenue moves from $2.62M in 2022 to $258.08K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

Measured against sales, the shares trade at 7.02 times revenue. On price-to-sales that is 3.1 times the Drug Manufacturers - Specialty & Generic median of 2.3. The medians here are taken across 103 Drug Manufacturers - Specialty & Generic companies that report the metric.

Annualized volatility over the trailing 4 years is 186.85%. Over the trailing twelve months the price has returned −95.80%. Measured over 3 years, that is −89.57% a year compounded.

Growth & Income

No dividend is on file for AKAN.

The strongest complete calendar year on file is 2023 at −70.47%; the weakest is 2024 at −95.45%. Of the 3 complete calendar years on file, 0 finished higher. 2026 is still running; the price is −67.45% year to date.